Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 29, 2006
Business Overview: Exelixis is a biopharmaceutical company focused on discovering and developing novel small-molecule therapies for cancer and other serious diseases. The company utilizes an integrated drug discovery platform to advance compounds from gene to drug. As of the reporting date, the company had filed 11 Investigational New Drug (IND) applications and maintained a pipeline of compounds in various stages of clinical and preclinical development, including Phase II candidates XL647, XL784, XL999, and XL880.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenues | $98.7 million | $76.0 million |
| Net Loss | $(101.5) million | $(84.4) million |
| Research & Development Expenses | $185.5 million | $141.1 million |
| General & Administrative Expenses | $39.1 million | $27.7 million |
| Cash and Cash Equivalents | $123.4 million | $81.3 million |
| Total Cash, Securities & Investments (including SEI) | $263.2 million | $210.5 million |
| Working Capital | $150.8 million | $86.5 million |
| Long-Term Debt (Principal) | $108.1 million | $106.9 million |
| Accumulated Deficit | $(705.3) million | $(603.8) million |
Note: The company does not report gross margins as it has no product sales revenue. Revenue is derived from collaboration agreements, license fees, and milestone payments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 30% to $98.7 million, driven primarily by increased amortization of upfront payments from new collaborations (Sankyo, Wyeth, Bristol-Myers Squibb) and milestone achievements (Wyeth, Helsinn, Bristol-Myers Squibb). This offset the conclusion of the Genoptera collaboration.
- Expense Increases: R&D expenses rose 31% to $185.5 million due to expanded clinical trial activities (Phase I and II) and the adoption of SFAS 123R, which added $11.2 million in stock-based compensation expense. G&A expenses increased 41% to $39.1 million, largely due to $6.3 million in stock-based compensation.
- Liquidity Position: Cash and cash equivalents increased significantly to $123.4 million, bolstered by a $90.5 million net proceeds from a common stock offering in October 2006 and a $40.0 million capital draw from Symphony Evolution, Inc. (SEI).
- Debt Repayment: The company repaid a $30.0 million convertible promissory note to PDL BioPharma in May 2006.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management anticipates that current cash resources and expected collaborator funding will support operations for at least 12 months following the reporting date. The company expects to continue incurring net losses as it advances its pipeline. Future capital requirements depend heavily on clinical trial results and the timing of milestone payments.
Material Risks and Contingencies
- XL999 Clinical Hold: Enrollment in the Phase II program for XL999 was suspended in November 2006, and the FDA placed a partial clinical hold in December 2006 due to serious cardiovascular adverse events. Further development depends on demonstrating that dose reduction can mitigate these risks.
- SEI Repurchase Obligation: Three key compounds (XL647, XL999, XL784) are licensed to Symphony Evolution, Inc. (SEI). If GlaxoSmithKline selects any of these for further development, Exelixis must repurchase all three from SEI. The repurchase price is the invested capital ($80 million) plus 25% annual interest. This creates a significant potential cash outflow.
- Financial Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million under its loan agreement with GlaxoSmithKline. As of year-end, the company was in compliance ($150.8M working capital; $253.5M cash/investments).
- Profitability: The company has a history of net losses and an accumulated deficit of $705.3 million. It expects to continue incurring losses for the foreseeable future.
Investor Verification Checklist
- XL999 Status: Verify the FDA's decision on lifting the partial clinical hold and the revised development plan for XL999.
- SEI Repurchase Trigger: Monitor GlaxoSmithKline's potential selection of XL647, XL999, or XL784, which would trigger a mandatory repurchase of all three assets from SEI at a compounded cost.
- Cash Burn Rate: Assess the sustainability of the $263.2 million cash position against the high R&D burn rate ($185.5M in 2006) and potential future capital raises.
- Collaboration Milestones: Track the achievement of milestones with GlaxoSmithKline, Bristol-Myers Squibb, and Genentech, which are critical for near-term revenue recognition.
- Stock-Based Compensation: Review the impact of SFAS 123R adoption on future expense reporting, as $17.6 million was recognized in 2006.